You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 盟科藥業升超10% MRX-4全球III期臨牀試驗國內首家中心啟動
格隆匯 04-07 10:33
格隆匯4月7日丨盟科藥業(688373.SH)升超10%,報9.8元,總市值64億元。上海盟科藥業股份有限公司宣佈其自主研發的抗革蘭陽性耐藥菌新藥注射用MRX-4序貫口服康替唑胺片治療糖尿病足感染的全球三期臨牀試驗國內首家中心啟動。康替唑胺片和MRX-4 是盟科藥業自主研發的具有全球知識產權的噁唑烷酮類1類抗菌創新藥。康替唑胺片已於2021年6月1日獲NMPA批准用於治療複雜性皮膚和軟組織感染,為全球首次獲批上市。MRX-4為盟科藥業在對康替唑胺片深入剖析和科學探究的基礎上,研發出的康替唑胺片的前藥。在注射用MRX-4 獲批上市後,臨牀醫生可選擇獨立使用注射用 MRX-4 靜脈給藥,或序貫口服康替唑胺片治療耐藥革蘭氏陽性菌導致的感染。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account